APTO Aptose Biosciences Inc.

7.62
-0.23  -3%
Previous Close 7.85
Open 7.84
Price To Book 21.17
Market Cap 581,205,739
Shares 76,264,806
Volume 369,979
Short Ratio
Av. Daily Volume 909,565
Stock charts supplied by TradingView

NewsSee all news

  1. Aptose to Present Early CG-806 Clinical Findings at the 25th Congress of the European Hematology Association

    SAN DIEGO and TORONTO, May 14, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differentiated therapeutics targeting the

  2. Aptose to Present at 2020 RBC Capital Markets Global Healthcare Virtual Conference

    SAN DIEGO and TORONTO, May 07, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of

  3. Aptose Biosciences Establishes New At-The-Market Facility

    SAN DIEGO and TORONTO, May 05, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differentiated agents that target the

  4. Aptose Reports Results for the First Quarter 2020

    CG-806 Phase 1 a/b Study in B Cell Malignancies Now Dosing in Fourth Cohort CG-806 Proposed Starting Dose for Upcoming Phase 1 Study in AML Identified Conference Call and Webcast at 5pm EDT Today SAN DIEGO and

  5. Aptose Presents Preliminary Clinical Data on CG-806 at AACR Virtual Annual Meeting 2020

    SAN DIEGO and TORONTO, April 27, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1b data noted favorable safety profile - December 7, 2019.
APTO-253
Acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
Phase 1 presentation at ASCO May 29, 2020.
CG-806
Chronic lymphocytic leukemia (CLL/SLL) or non-Hodgkin lymphomas (NHL)

Latest News

  1. Aptose to Present Early CG-806 Clinical Findings at the 25th Congress of the European Hematology Association

    SAN DIEGO and TORONTO, May 14, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differentiated therapeutics targeting the

  2. Aptose to Present at 2020 RBC Capital Markets Global Healthcare Virtual Conference

    SAN DIEGO and TORONTO, May 07, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of

  3. Aptose Biosciences Establishes New At-The-Market Facility

    SAN DIEGO and TORONTO, May 05, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differentiated agents that target the

  4. Aptose Reports Results for the First Quarter 2020

    CG-806 Phase 1 a/b Study in B Cell Malignancies Now Dosing in Fourth Cohort CG-806 Proposed Starting Dose for Upcoming Phase 1 Study in AML Identified Conference Call and Webcast at 5pm EDT Today SAN DIEGO and

  5. Aptose Presents Preliminary Clinical Data on CG-806 at AACR Virtual Annual Meeting 2020

    SAN DIEGO and TORONTO, April 27, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of

  6. Aptose Biosciences Files Proxy Statement, Announces Online Only Annual General Meeting

    SAN DIEGO and TORONTO, April 24, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differentiated agents that target the

  7. Aptose to Release First Quarter Ended March 31, 2020 Financial Results and Hold Conference Call on May 5, 2020

    SAN DIEGO and TORONTO, April 21, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of

  8. Aptose Reports Results for the Fourth Quarter and Full Year 2019

    SAN DIEGO and TORONTO, March 10, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differentiated agents that target the

  9. Aptose to Release Fourth Quarter and Year End December 31, 2019 Financial Results and Hold Conference Call on March 10, 2020

    SAN DIEGO and TORONTO, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of

  10. Aptose Biosciences to Host Key Opinion Leader Event Present at BIO CEO & Investor Conference

    SAN DIEGO and TORONTO, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of

  11. Aptose Biosciences to Present at Biotech Showcase™ 2020 Conference

    SAN DIEGO and TORONTO, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of

  12. Aptose Announces Closing of Public Offering of Common Shares

    SAN DIEGO and TORONTO, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), today announced the closing of its previously announced underwritten public offering

  13. Aptose Announces Pricing of Public Offering of Common Shares

    SAN DIEGO and TORONTO, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), today announced that it priced its previously announced underwritten public offering

  14. Aptose Announces Proposed Public Offering of Common Shares

    SAN DIEGO and TORONTO, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), today announced that it has commenced an underwritten public offering of its common

  15. Aptose Presents New Preclinical CG-806 Data at the 2019 ASH Annual Meeting

    SAN DIEGO and TORONTO, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose") (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying

  16. Aptose Presents Highlights From Corporate Event At ASH

    SAN DIEGO, TORONTO and ORLANDO, Fla., Dec. 07, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS) released highlights from a corporate event and clinical update today held at the 61st American

  17. Aptose Appoints Rafael Bejar, M.D., Ph.D., as Chief Medical Officer

    SAN DIEGO and TORONTO, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of

  18. Aptose to Present at 31st Annual Piper Jaffray Healthcare Conference

    SAN DIEGO and TORONTO, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of

  19. Aptose to Present at BIO-Europe Conference

    SAN DIEGO and TORONTO, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of

  20. Aptose to Present New CG-806 Data at the 2019 ASH Annual Meeting

    – Company to Hold Event During ASH –  – CG-806 Preclinical Abstracts Accepted for Presentation – SAN DIEGO and TORONTO, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose") (NASDAQ:APTO, TSX:APS), a

  21. Aptose Reports Results for the Third Quarter Ended September 30, 2019

    CG-806 Mutation Agnostic FLT3/BTK Inhibitor and APTO-253 MYC Inhibitor Safely Dose Escalate CLL Patient Treated with Second Dose Level of CG-806 Shows Evidence of Clinical Response Conference Call and Webcast at 5pm

  22. Aptose to Participate at 5th International Conference on Acute Myeloid Leukemia of the European School of Haematology (ESH)

    SAN DIEGO and TORONTO, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differentiated therapeutics targeting the

  23. Aptose to Participate in Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies

    SAN DIEGO and TORONTO, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target